US Physical Therapy Inc

US Physical Therapy Inc(USPH)股票分析

$88.650

+0.124 (+0.14%)收盘时

Loading chart…
最高
89.980
开盘
88.980
成交量加权均价
89.07
成交量
76.19K
市值
1.40B
最低
88.575
成交额
6.79M
企业价值/息税折旧摊销前利润(TTM)
13.60

U.S. Physical Therapy, Inc. is an operator of outpatient physical therapy clinics and provider of industrial injury prevention services. It owns and/or manages 795 outpatient physical therapy clinics in 45 states. Its reportable segments include the Physical Therapy Operations segment and the Industrial Injury Prevention Services (IIP) segment. The Physical Therapy Operations segment consists of physical therapy, speech therapy and occupational therapy clinics and home-care physical and speech therapy practices that provide pre- and post-operative care and treatment for a variety of orthopedic-related disorders, sports-related injuries, and rehabilitation of injured workers. The IIP segment includes onsite services for clients’ employees, including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers.

AI 分析 of US Physical Therapy Inc (USPH)

买入

US Physical Therapy Inc is a good buy right now due to its current price of $88.53 being close to analyst targets, with Barrington's target at $98 indicating a potential upside of 10.5%. The company reported a Q2 revenue of $214.06 million, which is an 8.5% year-over-year increase, showcasing strong growth despite a recent earnings miss. However, the main risk is the recent earnings miss, where EPS was $0.25, falling short of expectations by $0.53, which could affect investor confidence.

分析师评级(7)

上行空间 +14.50%
持有
2 买入
5 持有
0 卖出
当前: 88.65
最低
100.00
平均
101.50
最高
103.00

JPMorgan

2026-09-11

目标价

$95

增持

Barrington

2026-08-10

目标价

$98

跑赢大盘

Barrington

2026-05-13

目标价

$90

跑赢大盘

Citizens

2026-05-08

目标价

$98

跑赢大盘

Jefferies

2026-03-09

目标价

$102

买入

估值指标

US Physical Therapy Inc(USPH)当前预期市盈率为 27.25,5 年平均预期市盈率为 32.89。

预期市盈率

低估
5 年均值 P/E
32.89
当前P/E
27.25
高估
38.10
低估
27.68

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
19.07
当前EV/EBITDA
13.60
高估
22.49
低估
15.64

预期市销率

低估
5 年均值 P/S
1.93
当前P/S
1.45
高估
2.39
低估
1.48

Alphio AI 对 USPH 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%USPH

$100.54

情景价格

基

基准

基准 · 50%USPH

$97.38

情景价格

悲

悲观

悲观 · 25%USPH

$95.30

情景价格

持有 USPH 的大户

C

Copeland Capital Management, LLC

+ 持有USPH

-6.98%

3个月收益率

事件时间线

2026-09-21 (ET)

08:00:00

U.S. Physical Therapy Appoints Myra Davis to Board of Directors

2026-08-05 (ET)

16:30:00

USPH Reports Q2 Revenue of $214.1M, Beating Expectations

16:30:00

U.S. Physical Therapy Confirms FY26 Adjusted EBITDA Outlook of $102M-$106M

2026-07-02 (ET)

08:00:00

U.S. Physical Therapy Acquires 12-Clinic Practice, Holds 67% Stake

2026-05-06 (ET)

16:30:00

USPH Reaffirms 2026 EBITDA Guidance of $102M to $106M

资讯

USPH 常见问题 —— 由 Alphio AI 解答

U.S. Physical Therapy, Inc. is an operator of outpatient physical therapy clinics and provider of industrial injury prevention services. It owns and/or manages 795 outpatient physical therapy clinics in 45 states. Its reportable segments include the Physical Therapy Operations segment and the Industrial Injury Prevention Services (IIP) segment. The Physical Therapy Operations segment consists of physical therapy, speech therapy and occupational therapy clinics and home-care physical and speech therapy practices that provide pre- and post-operative care and treatment for a variety of orthopedic-related disorders, sports-related injuries, and rehabilitation of injured workers. The IIP segment includes onsite services for clients’ employees, including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).

US Physical Therapy Inc is a good buy right now due to its current price of $88.53 being close to analyst targets, with Barrington's target at $98 indicating a potential upside of 10.5%. The company reported a Q2 revenue of $214.06 million, which is an 8.5% year-over-year increase, showcasing strong growth despite a recent earnings miss. However, the main risk is the recent earnings miss, where EPS was $0.25, falling short of expectations by $0.53, which could affect investor confidence.

7 analysts cover USPH: 2 rate it Buy, 5 Hold and 0 Sell. The average price target is 101.50.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易